New drug EA5 passes first safety check in healthy volunteers
Knowledge-focused
Completed
This early-stage study tested a single dose of the experimental drug EA5 in 28 healthy adults to see if it is safe and how the body processes it. Participants were randomly assigned to receive either EA5 or a placebo, and neither they nor the doctors knew who got which. The goal …
Phase: PHASE1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC